Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Drug or technology

AV-1980R 60 µg

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 20, 2026 · PHASE 1 TRIAL

AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

ClinicalTrials.gov

Phase 1 trial of a novel tau vaccine in preclinical AD; no results reported in this registry record, and the primary focus is safety and tolerability rather than clinical efficacy.

PreliminaryAV-1980R 60 µg Alzheimer Disease AV-1980R 180 µg

Reported

Planned enrollment48

Age range65 to 80 years

AV-1980R dose levels20 µg, 60 µg, 180 µg

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support